In a few short years, biosimilars have driven down total cost of care in oncology through providing competition for expensive drugs, explained Christine Pfaff, RPh, senior regional director of operations, American Oncology Network (AON).
Just 5 years ago, providers were still getting educated on biosimilars and what they were, but since then, these products have driven down total cost of care, said Christine Pfaff, RPh, senior regional director of operations, American Oncology Network (AON).
At this year’s American Society of Clinical Oncology annual meeting, experts from AON presented an abstract on the impact of regional clinical pharmacists on selecting the most cost-effective biosimilar products. Through the biosimilar substitution program, AON’s practices saved $56.5 million in 2022.
Oncology biosimilars have seen the strongest adoption. Of the 37 FDA-approved biosimilars on the market in the United States, 22 of them have cancer indications.
Transcript
What is an innovation that has changed oncology care over the last few years?
Biosimilars and products that are in that category and how we've seen our total cost of care go down with biosimilar use. Maybe 5 years ago, I think, we talked about “Are biosimilars the same or not?” And we were kind of getting through that understanding with the physicians, and it's not a generic, you know, so it's a bit different. And now that I feel like they are on board with the efficacy of the drugs, it's really trying to figure out how adding those products to our formulary and getting them to patients helps reduce total cost of care.
When you asked about innovation, I think biosimilars are a huge player in that for our practice, specifically, and really trying to utilize biosimilars to reduce our total cost of care for patients. It's been huge for us. I mean, a lot of the drugs were supportive care products—your neutropenia drugs or your anemia drugs—and those were very expensive. So, I mean, we've been pleased so far.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More